Imagenebio (NASDAQ: IMA) CMO Dr. Yufang Lu to resign with transition role

Rhea-AI Filing Summary

Imagenebio, Inc. reported that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., has given notice of her resignation effective December 31, 2025. The company states that Dr. Lu’s decision is not due to any disagreement regarding its operations, policies, or practices, which suggests the change is not driven by internal conflict.

Imagenebio is beginning a search for a new Chief Medical Officer, an important role overseeing its medical and clinical programs. Dr. Lu is expected to provide transition advisory services after her resignation date, helping to maintain continuity in the company’s clinical and medical activities while leadership responsibilities are handed over to her eventual successor.

Insights

Biotech governance and clinical strategy analyst

Imagenebio’s Chief Medical Officer is resigning, with a planned transition and no stated internal dispute.

Imagenebio, Inc. disclosed that Chief Medical Officer Yufang Lu, M.D., Ph.D. will resign effective December 31, 2025. The company explicitly notes that her departure is not due to any disagreement on operations, policies, or practices, which frames this as an orderly leadership change rather than a conflict-driven exit.

The Chief Medical Officer role is central in a biotech business because it oversees clinical development and medical strategy. Imagenebio plans to search for a replacement and expects Dr. Lu to provide transition advisory services after her resignation date. This arrangement is designed to preserve continuity in clinical and medical work while the company recruits and onboards a new executive.

The practical impact will depend on how quickly a suitably experienced successor is identified and how effectively responsibilities are handed off around and after December 31, 2025. Subsequent company communications may provide more detail on the new appointee and any shifts in clinical priorities.

NASDAQ false 0001835579 0001835579 2025-12-12 2025-12-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 12, 2025, Yufang Lu, M.D., Ph.D., our Chief Medical Officer, provided notice of her resignation, effective December 31, 2025. Dr. Lu’s resignation was not due to any disagreement on any matter relating to our operations, policies or practices. We are conducting a search for Dr. Lu’s replacement. Dr. Lu is expected to provide transition advisory services following her resignation date.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: December 18, 2025				By:		/s/ Kristin Yarema
						Kristin Yarema, Ph.D.
						Chief Executive Officer

FAQ

What leadership change did Imagenebio (IMA) disclose on December 12, 2025?

Imagenebio reported that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., has submitted her resignation, which will be effective on December 31, 2025.

Why is Imagenebio’s Chief Medical Officer Dr. Yufang Lu resigning?

Imagenebio states that Dr. Lu’s resignation is not due to any disagreement regarding the company’s operations, policies, or practices; no additional reasons are provided.

When will Dr. Yufang Lu’s resignation from Imagenebio (IMA) take effect?

Dr. Lu’s resignation as Chief Medical Officer is effective on December 31, 2025, following her notice given on December 12, 2025.

Is Imagenebio (IMA) planning to replace its Chief Medical Officer after Dr. Lu resigns?

Yes. Imagenebio indicates it is conducting a search for a replacement Chief Medical Officer following Dr. Lu’s resignation.

Will Dr. Yufang Lu have any ongoing role at Imagenebio after December 31, 2025?

Yes. Imagenebio expects Dr. Lu to provide transition advisory services after her resignation date to support continuity.

Did Imagenebio report any disagreements tied to Dr. Lu’s resignation?

No. The company specifically notes that Dr. Lu’s resignation was not due to any disagreement on matters relating to operations, policies, or practices.